首页 > 最新文献

Therapeutic Advances in Respiratory Disease最新文献

英文 中文
Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study. 间质性肺病急性加重与进行性肺纤维化之间的关系:一项回顾性队列研究。
IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666241276800
Liying Zhai, Zhiqiang Wang, Wencheng Yu

Background: Acute exacerbation (AE) refers to rapidly progressive respiratory deterioration in the clinical course of interstitial lung disease (ILD). Progressive pulmonary fibrosis (PPF) is the chronic progressive phenotype of ILD. No study has investigated the relationship between AE and PPF in ILD.

Objectives: We aimed to determine the association between AE and PPF in ILD patients.

Design: A retrospective cohort study.

Methods: A total of 414 patients hospitalised for ILD were included in our study. The clinical presentations, radiographic features and laboratory findings of the patients were reviewed.

Results: AE was present in 120 (29.0%) ILD patients and was associated with a higher risk of death than non-AE patients in the whole cohort (HR 2.893; 95% CI, 1.847-4.529; p < 0.001). However, the significant difference disappeared when stratified by PPF (HR 1.192; 95% CI, 0.633-2.247; p = 0.586) and non-PPF (HR 1.113; 95% CI, 0.384-3.223; p = 0.844). In addition, the adverse effect of PPF on prognosis remained consistent in both AE and non-AE patients. Multivariable logistic regression analysis showed that compared with non-PPF patients, only age was a risk factor for PPF in AE-ILD, while the risk factors for PPF in the non-AE group were age, definite usual interstitial pneumonia and mediastinal lymph node enlargement.

Conclusion: In the context of ILD, both AE and PPF were found to be associated with poor prognosis. However, the adverse effect of AE on prognosis disappeared when PPF was considered as a stratification feature, whereas the adverse effect of PPF on prognosis persisted in both AE and non-AE individuals. Therefore, it is important to investigate effective strategies to prevent disease progression after AE. Increased recognition and attention to PPF and early antifibrotic therapy at the appropriate time is also warranted.

背景:急性加重(AE)是指在间质性肺病(ILD)的临床过程中,呼吸功能急剧恶化。进行性肺纤维化(PPF)是 ILD 的慢性进展表型。目前还没有研究调查 ILD 中 AE 与 PPF 之间的关系:设计:一项回顾性队列研究:设计:一项回顾性队列研究:我们的研究共纳入了 414 名因 ILD 而住院的患者。研究回顾了患者的临床表现、影像学特征和实验室检查结果:120例(29.0%)ILD患者出现AE,与非AE患者(HR 2.893; 95% CI, 1.847-4.529; p p = 0.586)和非PPF患者(HR 1.113; 95% CI, 0.384-3.223; p = 0.844)相比,AE患者的死亡风险更高。此外,PPF对AE和非AE患者预后的不利影响仍然一致。多变量逻辑回归分析显示,与非PPF患者相比,AE-ILD患者中只有年龄是PPF的危险因素,而非AE组PPF的危险因素是年龄、明确的惯常间质性肺炎和纵隔淋巴结肿大:结论:就 ILD 而言,AE 和 PPF 都与预后不良有关。然而,当把 PPF 作为分层特征时,AE 对预后的不利影响消失了,而 PPF 对预后的不利影响在 AE 和非 AE 患者中都持续存在。因此,研究预防 AE 后疾病进展的有效策略非常重要。此外,还需要提高对PPF的认识和关注,并在适当的时候进行早期抗纤维化治疗。
{"title":"Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study.","authors":"Liying Zhai, Zhiqiang Wang, Wencheng Yu","doi":"10.1177/17534666241276800","DOIUrl":"10.1177/17534666241276800","url":null,"abstract":"<p><strong>Background: </strong>Acute exacerbation (AE) refers to rapidly progressive respiratory deterioration in the clinical course of interstitial lung disease (ILD). Progressive pulmonary fibrosis (PPF) is the chronic progressive phenotype of ILD. No study has investigated the relationship between AE and PPF in ILD.</p><p><strong>Objectives: </strong>We aimed to determine the association between AE and PPF in ILD patients.</p><p><strong>Design: </strong>A retrospective cohort study.</p><p><strong>Methods: </strong>A total of 414 patients hospitalised for ILD were included in our study. The clinical presentations, radiographic features and laboratory findings of the patients were reviewed.</p><p><strong>Results: </strong>AE was present in 120 (29.0%) ILD patients and was associated with a higher risk of death than non-AE patients in the whole cohort (HR 2.893; 95% CI, 1.847-4.529; <i>p</i> < 0.001). However, the significant difference disappeared when stratified by PPF (HR 1.192; 95% CI, 0.633-2.247; <i>p</i> = 0.586) and non-PPF (HR 1.113; 95% CI, 0.384-3.223; <i>p</i> = 0.844). In addition, the adverse effect of PPF on prognosis remained consistent in both AE and non-AE patients. Multivariable logistic regression analysis showed that compared with non-PPF patients, only age was a risk factor for PPF in AE-ILD, while the risk factors for PPF in the non-AE group were age, definite usual interstitial pneumonia and mediastinal lymph node enlargement.</p><p><strong>Conclusion: </strong>In the context of ILD, both AE and PPF were found to be associated with poor prognosis. However, the adverse effect of AE on prognosis disappeared when PPF was considered as a stratification feature, whereas the adverse effect of PPF on prognosis persisted in both AE and non-AE individuals. Therefore, it is important to investigate effective strategies to prevent disease progression after AE. Increased recognition and attention to PPF and early antifibrotic therapy at the appropriate time is also warranted.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241276800"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study. 针对难治性或不明原因慢性咳嗽成人的莱斯特咳嗽问卷的内容有效性:一项定性访谈研究。
IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666241274261
Allison Martin Nguyen, Carmen La Rosa, Alexandra G Cornell, Mandel R Sher, Jonathan A Bernstein, Surinder S Birring, Carla DeMuro Romano, Margaret Mayorga, Mirline Milien, Claire Ervin

Background: Chronic cough, a cough lasting >8 weeks, includes refractory chronic cough (RCC) and unexplained chronic cough (UCC). Patient-reported outcome (PRO) measures are needed to better understand chronic cough impacts that matter most to patients. The 19-item Leicester Cough Questionnaire (LCQ), an existing PRO measure of chronic cough, assesses impacts of cough across physical, psychological, and social domains. However, the content validity of the LCQ evaluating these concepts in patients with RCC/UCC had not been established.

Objectives: To evaluate the content validity of the LCQ in patients with RCC/UCC.

Design: A cross-sectional, qualitative interview study.

Methods: First, previously completed qualitative interview results in adults with RCC/UCC (N = 30) were evaluated and mapped to LCQ concepts. Next, a clinical cough expert reviewed each LCQ item and assessed the salience of its concepts for patients with RCC/UCC. Finally, semistructured interviews-including both concept elicitation and cognitive debriefing-were conducted in adults with RCC/UCC (N = 20) to elicit a comprehensive set of participant experiences and to assess the appropriateness of using the LCQ in this population.

Results: Concepts reported in the past and present qualitative interviews were included across all LCQ items, and most impacts reported to be the "most bothersome" were assessed in the LCQ. In the current study, all participants indicated that reduced cough frequency would be an important treatment target. During cognitive debriefing, each LCQ item was endorsed by ⩾70% of participants. Additionally, participants were generally able to understand, recall, and select a response for each LCQ item. All participants and the clinical expert indicated that the LCQ was appropriate and assessed the impacts most relevant to patients with RCC/UCC.

Conclusion: Our findings support the content validity of the LCQ and demonstrate that this measure is fit-for-purpose and includes important cough impacts in adults with RCC/UCC.

背景:慢性咳嗽是指持续 8 周以上的咳嗽,包括难治性慢性咳嗽 (RCC) 和原因不明的慢性咳嗽 (UCC)。为了更好地了解慢性咳嗽对患者的影响,需要采用患者报告结果(PRO)测量方法。由 19 个项目组成的莱斯特咳嗽问卷(LCQ)是一种现有的慢性咳嗽患者报告结果测量方法,可评估咳嗽对身体、心理和社会领域的影响。然而,在 RCC/UCC 患者中评估这些概念的 LCQ 的内容有效性尚未确定:评估 LCQ 在 RCC/UCC 患者中的内容有效性:设计:横断面定性访谈研究:首先,对之前完成的 RCC/UCC 成人定性访谈结果(N = 30)进行评估,并将其与 LCQ 概念进行映射。然后,由临床咳嗽专家对 LCQ 的每个项目进行审查,并评估其概念对 RCC/UCC 患者的显著性。最后,对患有 RCC/UCC 的成人(N = 20)进行了半结构式访谈,包括概念诱导和认知汇报,以获得一套全面的参与者经验,并评估 LCQ 在这一人群中的适用性:结果:过去和现在的定性访谈中报告的概念都包含在 LCQ 的所有项目中,LCQ 评估了大多数报告为 "最困扰 "的影响。在本次研究中,所有参与者都表示,减少咳嗽次数将是一个重要的治疗目标。在认知汇报过程中,每个 LCQ 项目都得到了 70% 参与者的认可。此外,参与者一般都能理解、回忆并选择每个 LCQ 项目的答案。所有参与者和临床专家都表示,LCQ 是适当的,并且评估了与 RCC/UCC 患者最相关的影响:我们的研究结果支持 LCQ 的内容效度,并证明该测量方法符合目的,且包含了对 RCC/UCC 成人患者的重要咳嗽影响。
{"title":"Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study.","authors":"Allison Martin Nguyen, Carmen La Rosa, Alexandra G Cornell, Mandel R Sher, Jonathan A Bernstein, Surinder S Birring, Carla DeMuro Romano, Margaret Mayorga, Mirline Milien, Claire Ervin","doi":"10.1177/17534666241274261","DOIUrl":"10.1177/17534666241274261","url":null,"abstract":"<p><strong>Background: </strong>Chronic cough, a cough lasting >8 weeks, includes refractory chronic cough (RCC) and unexplained chronic cough (UCC). Patient-reported outcome (PRO) measures are needed to better understand chronic cough impacts that matter most to patients. The 19-item Leicester Cough Questionnaire (LCQ), an existing PRO measure of chronic cough, assesses impacts of cough across physical, psychological, and social domains. However, the content validity of the LCQ evaluating these concepts in patients with RCC/UCC had not been established.</p><p><strong>Objectives: </strong>To evaluate the content validity of the LCQ in patients with RCC/UCC.</p><p><strong>Design: </strong>A cross-sectional, qualitative interview study.</p><p><strong>Methods: </strong>First, previously completed qualitative interview results in adults with RCC/UCC (<i>N</i> = 30) were evaluated and mapped to LCQ concepts. Next, a clinical cough expert reviewed each LCQ item and assessed the salience of its concepts for patients with RCC/UCC. Finally, semistructured interviews-including both concept elicitation and cognitive debriefing-were conducted in adults with RCC/UCC (<i>N</i> = 20) to elicit a comprehensive set of participant experiences and to assess the appropriateness of using the LCQ in this population.</p><p><strong>Results: </strong>Concepts reported in the past and present qualitative interviews were included across all LCQ items, and most impacts reported to be the \"most bothersome\" were assessed in the LCQ. In the current study, all participants indicated that reduced cough frequency would be an important treatment target. During cognitive debriefing, each LCQ item was endorsed by ⩾70% of participants. Additionally, participants were generally able to understand, recall, and select a response for each LCQ item. All participants and the clinical expert indicated that the LCQ was appropriate and assessed the impacts most relevant to patients with RCC/UCC.</p><p><strong>Conclusion: </strong>Our findings support the content validity of the LCQ and demonstrate that this measure is fit-for-purpose and includes important cough impacts in adults with RCC/UCC.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241274261"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A simple and efficient clinical prediction scoring system to identify malignant pleural effusion. 识别恶性胸腔积液的简单高效临床预测评分系统。
IF 4.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666231223002
Shuyan Wang, Jing An, Xueru Hu, Tingting Zeng, Ping Li, Jiangyue Qin, Yongchun Shen, Tao Wang, Fuqiang Wen

Background: Early diagnosis of malignant pleural effusion (MPE) is of great significance. Current prediction models are not simple enough to be widely used in heavy clinical work.

Objectives: We aimed to develop a simple and efficient clinical prediction scoring system to distinguish MPE from benign pleural effusion (BPE).

Design: This retrospective study involved patients with MPE or BPE who were admitted in West China Hospital from December 2010 to September 2016.

Methods: Patients were divided into training, testing, and validation set. Prediction model was developed from training set and modified to a scoring system. The diagnostic efficacy and clinical benefits of the scoring system were estimated in all three sets.

Results: Finally, 598 cases of MPE and 1094 cases of BPE were included. Serum neuron-specific enolase, serum cytokeratin 19 fragment (CYFRA21-1), pleural carcinoembryonic antigen (CEA), and ratio of pleural CEA to serum CEA were selected to establish the prediction models in training set, which were modified to the scoring system with scores of 6, 8, 10, and 9 points, respectively. Patients with scores >12 points have high MPE risk while ⩽12 points have low MPE risk. The scoring system has a high predictive value and good clinical benefits to differentiate MPE from BPE or lung-specific MPE from BPE.

Conclusion: This study developed a simple clinical prediction scoring system and was proven to have good clinical benefits, and it may help clinicians to separate MPE from BPE.

背景:恶性胸腔积液(MPE)的早期诊断意义重大。目前的预测模型不够简单,无法广泛应用于繁重的临床工作:我们旨在开发一种简单高效的临床预测评分系统,以区分恶性胸腔积液(MPE)和良性胸腔积液(BPE):这项回顾性研究涉及2010年12月至2016年9月在华西医院住院的MPE或BPE患者:将患者分为训练集、测试集和验证集。根据训练集建立预测模型,并修改为评分系统。对三组评分系统的诊断效果和临床效益进行了评估:结果:最终纳入了 598 例 MPE 和 1094 例 BPE。选择血清神经元特异性烯醇化酶、血清细胞角蛋白 19 片段(CYFRA21-1)、胸膜癌胚抗原(CEA)、胸膜癌胚抗原与血清癌胚抗原的比值建立训练集预测模型,并将其修改为评分系统,评分分别为 6 分、8 分、10 分和 9 分。评分大于 12 分的患者具有高 MPE 风险,而评分小于 12 分的患者具有低 MPE 风险。该评分系统在区分 MPE 与 BPE 或肺特异性 MPE 与 BPE 方面具有较高的预测价值和良好的临床效益:本研究建立了一个简单的临床预测评分系统,并被证明具有良好的临床效益,可帮助临床医生区分 MPE 和 BPE。
{"title":"A simple and efficient clinical prediction scoring system to identify malignant pleural effusion.","authors":"Shuyan Wang, Jing An, Xueru Hu, Tingting Zeng, Ping Li, Jiangyue Qin, Yongchun Shen, Tao Wang, Fuqiang Wen","doi":"10.1177/17534666231223002","DOIUrl":"10.1177/17534666231223002","url":null,"abstract":"<p><strong>Background: </strong>Early diagnosis of malignant pleural effusion (MPE) is of great significance. Current prediction models are not simple enough to be widely used in heavy clinical work.</p><p><strong>Objectives: </strong>We aimed to develop a simple and efficient clinical prediction scoring system to distinguish MPE from benign pleural effusion (BPE).</p><p><strong>Design: </strong>This retrospective study involved patients with MPE or BPE who were admitted in West China Hospital from December 2010 to September 2016.</p><p><strong>Methods: </strong>Patients were divided into training, testing, and validation set. Prediction model was developed from training set and modified to a scoring system. The diagnostic efficacy and clinical benefits of the scoring system were estimated in all three sets.</p><p><strong>Results: </strong>Finally, 598 cases of MPE and 1094 cases of BPE were included. Serum neuron-specific enolase, serum cytokeratin 19 fragment (CYFRA21-1), pleural carcinoembryonic antigen (CEA), and ratio of pleural CEA to serum CEA were selected to establish the prediction models in training set, which were modified to the scoring system with scores of 6, 8, 10, and 9 points, respectively. Patients with scores >12 points have high MPE risk while ⩽12 points have low MPE risk. The scoring system has a high predictive value and good clinical benefits to differentiate MPE from BPE or lung-specific MPE from BPE.</p><p><strong>Conclusion: </strong>This study developed a simple clinical prediction scoring system and was proven to have good clinical benefits, and it may help clinicians to separate MPE from BPE.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666231223002"},"PeriodicalIF":4.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10775726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139378303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profile of cough triggers and their relationship with capsaicin cough sensitivity in chronic cough. 慢性咳嗽患者的咳嗽诱因及其与辣椒素咳嗽敏感性的关系。
IF 4.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666231225562
Tingting Xu, Zhiyin Chen, Chen Zhan, Wenzhi Zhan, Fang Yi, Kefang Lai

Background: Cough hypersensitivity is an important part of the neurophysiology of cough, which presents with increased cough response to a lower level of stimuli or triggers. Classification of stimuli might bring about additional insight into the underlying mechanisms and management.

Objectives: This study investigated the profile of cough triggers in chronic cough patients and their relationship with capsaicin cough sensitivity.

Design: This was a cross-sectional observational study.

Methods: We enrolled patients with different causes of chronic cough from 2006 to 2021. Cough triggers were defined as cough response to chemical triggers, mechanical triggers, meal triggers, or thermal trigger. Cough sensitivity to capsaicin was evaluated by the capsaicin challenge test, which was expressed as the lowest concentration of capsaicin inducing 5 or more coughing (C5).

Results: Among 1211 patients with chronic cough, 1107 (91.4%) patients reported at least one cough trigger. Chemical triggers (66.9%) were the most common cough triggers, followed by thermal exposure (50.6%), mechanical triggers (48.2%), and meal triggers (21.2%). There was no difference in the proportion of chemical triggers among different etiologies. Patients with refractory chronic cough reported the highest prevalence of cough triggers (97.1%). A higher number of meal triggers (34.9%) was associated with gastroesophageal reflux-related cough, and meal triggers and mechanical triggers were more common in refractory chronic cough. Among 254 patients who completed capsaicin challenge test, both the number of total triggers and the number of chemical triggers had a significant but mild correlation with capsaicin cough sensitivity.

Conclusion: Cough hypersensitivity as reflected by a variety of cough triggers is a common feature in chronic cough patients, but different etiologies present specific profiles of cough triggers, which could not be evaluated comprehensively by capsaicin cough sensitivity.

背景:咳嗽超敏反应是咳嗽神经生理学的一个重要组成部分,表现为对较低水平的刺激或诱因的咳嗽反应增强。对刺激物进行分类可能有助于深入了解其潜在机制和治疗方法:本研究调查了慢性咳嗽患者的咳嗽诱因概况及其与辣椒素咳嗽敏感性的关系:设计:这是一项横断面观察研究:我们在 2006 年至 2021 年期间招募了不同病因的慢性咳嗽患者。咳嗽诱因被定义为对化学诱因、机械诱因、进餐诱因或热诱因的咳嗽反应。通过辣椒素挑战测试评估咳嗽对辣椒素的敏感性,以最低浓度的辣椒素引起5次或5次以上咳嗽(C5)表示:在 1211 名慢性咳嗽患者中,有 1107 名(91.4%)患者报告至少有一种咳嗽诱因。化学诱因(66.9%)是最常见的咳嗽诱因,其次是热暴露(50.6%)、机械诱因(48.2%)和进餐诱因(21.2%)。不同病因中化学诱因所占的比例没有差异。难治性慢性咳嗽患者报告的咳嗽诱因发生率最高(97.1%)。与胃食管反流相关的咳嗽患者有较多的进餐诱因(34.9%),而进餐诱因和机械性诱因在难治性慢性咳嗽中更为常见。在完成辣椒素挑战测试的 254 名患者中,总诱发因素和化学诱发因素的数量与辣椒素咳嗽敏感性有显著但轻微的相关性:结论:由多种咳嗽诱因反映出的咳嗽过敏症是慢性咳嗽患者的共同特征,但不同病因的咳嗽诱因具有特定的特征,而这些特征无法通过辣椒素咳嗽敏感性进行全面评估。
{"title":"Profile of cough triggers and their relationship with capsaicin cough sensitivity in chronic cough.","authors":"Tingting Xu, Zhiyin Chen, Chen Zhan, Wenzhi Zhan, Fang Yi, Kefang Lai","doi":"10.1177/17534666231225562","DOIUrl":"10.1177/17534666231225562","url":null,"abstract":"<p><strong>Background: </strong>Cough hypersensitivity is an important part of the neurophysiology of cough, which presents with increased cough response to a lower level of stimuli or triggers. Classification of stimuli might bring about additional insight into the underlying mechanisms and management.</p><p><strong>Objectives: </strong>This study investigated the profile of cough triggers in chronic cough patients and their relationship with capsaicin cough sensitivity.</p><p><strong>Design: </strong>This was a cross-sectional observational study.</p><p><strong>Methods: </strong>We enrolled patients with different causes of chronic cough from 2006 to 2021. Cough triggers were defined as cough response to chemical triggers, mechanical triggers, meal triggers, or thermal trigger. Cough sensitivity to capsaicin was evaluated by the capsaicin challenge test, which was expressed as the lowest concentration of capsaicin inducing 5 or more coughing (C5).</p><p><strong>Results: </strong>Among 1211 patients with chronic cough, 1107 (91.4%) patients reported at least one cough trigger. Chemical triggers (66.9%) were the most common cough triggers, followed by thermal exposure (50.6%), mechanical triggers (48.2%), and meal triggers (21.2%). There was no difference in the proportion of chemical triggers among different etiologies. Patients with refractory chronic cough reported the highest prevalence of cough triggers (97.1%). A higher number of meal triggers (34.9%) was associated with gastroesophageal reflux-related cough, and meal triggers and mechanical triggers were more common in refractory chronic cough. Among 254 patients who completed capsaicin challenge test, both the number of total triggers and the number of chemical triggers had a significant but mild correlation with capsaicin cough sensitivity.</p><p><strong>Conclusion: </strong>Cough hypersensitivity as reflected by a variety of cough triggers is a common feature in chronic cough patients, but different etiologies present specific profiles of cough triggers, which could not be evaluated comprehensively by capsaicin cough sensitivity.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666231225562"},"PeriodicalIF":4.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10860467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Additional EBUS-guided intralesional amphotericin B injection combined systemic intravenous therapy in pulmonary mucormycosis: a case report. 肺粘液瘤病的额外 EBUS 引导下局部注射两性霉素 B 联合全身静脉治疗:病例报告。
IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666241267242
Yang Wang, Weiwei Ning, Chao Liu, Nan Su, Qingqing Zhu, Yanbin Chen, Cheng Chen

Mucormycosis is an invasive fungal infection that can result in severe lung infections, with pulmonary mucormycosis (PM) being one of the most prevalent manifestations. Prompt diagnosis is crucial for patient survival, as PM often exhibits rapid clinical progression and carries a high fatality rate. Broncho-alveolar lavage fluid or endobronchial biopsy (EBB) has been commonly employed for diagnosing PM, although there is limited mention of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the literature. In this report, we present a case of PM in a patient with diabetes. While EBB did not yield evidence of Rhizopus infection, a definitive diagnosis was obtained through EBUS-TBNA. The patient underwent combination therapy, including oral medication, nebulization, and EBUS-guided intrafocal amphotericin B injection, which resulted in significant improvement following the failure of initial therapy with amphotericin B injection cholesterol sulfate complex. Our case highlights the potential of EBUS-TBNA not only for mediastinal lymphadenopathy but also for obtaining extraluminal lesion specimens. Furthermore, for patients with an inadequate response to mono-therapy and no access to surgical therapy, the addition of EBUS-guided intralesional amphotericin B injection to systemic intravenous therapy may yield unexpected effects.

粘孢子菌病是一种侵袭性真菌感染,可导致严重的肺部感染,其中肺粘孢子菌病(PM)是最常见的表现之一。及时诊断对患者的存活至关重要,因为肺粘孢子菌病通常临床进展迅速,致死率高。支气管肺泡灌洗液或支气管内活检(EBB)通常被用于诊断真菌性支气管炎,但文献中提及支气管内超声引导下经支气管针吸术(EBUS-TBNA)的病例有限。在本报告中,我们介绍了一例糖尿病患者的 PM。虽然 EBB 没有发现根霉菌感染的证据,但通过 EBUS-TBNA 获得了明确诊断。患者接受了综合治疗,包括口服药物、雾化吸入和在 EBUS 引导下病灶内注射两性霉素 B。我们的病例凸显了 EBUS-TBNA 的潜力,它不仅可用于纵隔淋巴结病,还可用于获取腔外病变标本。此外,对于单药治疗效果不佳且无法接受手术治疗的患者,在全身静脉注射治疗的基础上增加 EBUS 引导下的区域内两性霉素 B 注射可能会产生意想不到的效果。
{"title":"Additional EBUS-guided intralesional amphotericin B injection combined systemic intravenous therapy in pulmonary mucormycosis: a case report.","authors":"Yang Wang, Weiwei Ning, Chao Liu, Nan Su, Qingqing Zhu, Yanbin Chen, Cheng Chen","doi":"10.1177/17534666241267242","DOIUrl":"10.1177/17534666241267242","url":null,"abstract":"<p><p>Mucormycosis is an invasive fungal infection that can result in severe lung infections, with pulmonary mucormycosis (PM) being one of the most prevalent manifestations. Prompt diagnosis is crucial for patient survival, as PM often exhibits rapid clinical progression and carries a high fatality rate. Broncho-alveolar lavage fluid or endobronchial biopsy (EBB) has been commonly employed for diagnosing PM, although there is limited mention of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the literature. In this report, we present a case of PM in a patient with diabetes. While EBB did not yield evidence of Rhizopus infection, a definitive diagnosis was obtained through EBUS-TBNA. The patient underwent combination therapy, including oral medication, nebulization, and EBUS-guided intrafocal amphotericin B injection, which resulted in significant improvement following the failure of initial therapy with amphotericin B injection cholesterol sulfate complex. Our case highlights the potential of EBUS-TBNA not only for mediastinal lymphadenopathy but also for obtaining extraluminal lesion specimens. Furthermore, for patients with an inadequate response to mono-therapy and no access to surgical therapy, the addition of EBUS-guided intralesional amphotericin B injection to systemic intravenous therapy may yield unexpected effects.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241267242"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early outcomes of radical surgery in non-small-cell lung cancer patients with and without COVID-19 history: a multi-center real-world study. 有COVID-19病史和无COVID-19病史的非小细胞肺癌患者根治术的早期疗效:一项多中心真实世界研究。
IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666241298794
Hanbo Pan, Hang Chen, Wanyu Li, Yu Tian, Zhen Ge, Weicheng Kong, Zenan Gu, Ningyuan Zou, Hongda Zhu, Jiaqi Zhang, Yixing Tao, Junwei Ning, Jia Huang, Hui Yin, Ming Zhang, Chengwei Zhou, Hui Wang, Guodong Xu, Qingquan Luo

Background: Coronavirus disease (COVID)-19 can lead to chronic lung damage and respiratory issues, potentially increasing surgical difficulty and risk for patients with non-small-cell lung cancer (NSCLC). However, the impacts of a COVID-19 history on early outcomes in NSCLC patients remain controversial.

Objectives: To evaluate the effect of COVID-19 history on early outcomes in NSCLC patients and identify high-risk groups undergoing radical resection based on the largest Chinese multi-center real-world data to date.

Design: Multi-center retrospective cohort study.

Methods: NSCLC patients with (POCVD group) or without (NCVD group) a history of COVID-19 who underwent radical surgery at six institutions from January 2022 to January 2024 were retrospectively reviewed from a prospectively maintained database. Propensity-score matching (PSM) was utilized to minimize patient selection bias.

Results: Out of 7932 cases included, PSM resulted in 3021 cases per group. The two groups were comparable regarding the proportion of male patients (52.0% vs 51.6%) and those aged ⩾70 years (13.3% vs 13.8%). Although the two groups had comparable incidences of complications with Clavien-Dindo grades ⩾II (13.0% vs 14.4%, p = 0.117), the POCVD group had longer surgical durations (120.87 ± 40.23 min vs 110.74 ± 38.76 min, mean difference (95% confidence interval (CI) = 10.13 (8.138-12.122)) and higher rates of respiratory complications than the NCVD group. Subgroup logistic regression analysis indicated that patients aged ⩾70 years (odds ratio (OR) (95% CI) = 1.322 (1.022-1.876)) and those with a smoking history (OR (95% CI) = 1.235 (1.008-1.543)) had an increased risk of developing complications with Clavien-Dindo grades ⩾II. Further analysis confirmed that these high-risk patients experienced extended surgical durations, longer chest tube drainage, and prolonged postoperative hospital stay, along with increased postoperative respiratory complications following COVID-19.

Conclusion: Generally, radical resection is safe for NSCLC patients with a COVID-19 history. However, these patients experienced prolonged surgical durations and a higher incidence of postoperative respiratory complications compared to those without a COVID-19 history. In addition, individuals aged ⩾70 years or with a smoking history faced elevated surgical risks following COVID-19.

背景:冠状病毒病(COVID)-19可导致慢性肺损伤和呼吸系统问题,可能会增加非小细胞肺癌(NSCLC)患者的手术难度和风险。然而,COVID-19病史对NSCLC患者早期预后的影响仍存在争议:基于迄今为止最大的中国多中心真实世界数据,评估 COVID-19 病史对 NSCLC 患者早期预后的影响,并识别接受根治性切除术的高危人群:多中心回顾性队列研究:回顾性分析前瞻性数据库中2022年1月至2024年1月期间在6家医疗机构接受根治术的有COVID-19病史(POCVD组)或无COVID-19病史(NCVD组)的NSCLC患者。采用倾向分数匹配法(PSM)最大程度地减少了患者的选择偏差:结果:在纳入的 7932 个病例中,PSM 得出每组 3021 个病例。两组男性患者的比例(52.0% vs 51.6%)和年龄⩾70 岁患者的比例(13.3% vs 13.8%)相当。虽然两组患者的 Clavien-Dindo ⩾II 级并发症发生率相当(13.0% vs 14.4%,P = 0.117),但与 NCVD 组相比,POCVD 组的手术时间更长(120.87 ± 40.23 分钟 vs 110.74 ± 38.76 分钟,平均差异(95% 置信区间 (CI) = 10.13 (8.138-12.122)),呼吸系统并发症发生率更高。亚组逻辑回归分析表明,年龄⩾70 岁的患者(比值比 (OR) (95% CI) = 1.322 (1.022-1.876))和有吸烟史的患者(比值比 (95% CI) = 1.235 (1.008-1.543))发生 Clavien-Dindo Ⅱ级并发症的风险更高。进一步分析证实,这些高风险患者在 COVID-19 之后经历了更长的手术时间、更长时间的胸管引流、更长的术后住院时间,以及更多的术后呼吸系统并发症:结论:一般来说,对有 COVID-19 病史的 NSCLC 患者进行根治性切除是安全的。结论:一般来说,有 COVID-19 病史的 NSCLC 患者接受根治性切除术是安全的,但与无 COVID-19 病史的患者相比,这些患者的手术时间更长,术后呼吸系统并发症的发生率更高。此外,年龄⩾70岁或有吸烟史的患者在接受COVID-19手术后面临的手术风险更高。
{"title":"Early outcomes of radical surgery in non-small-cell lung cancer patients with and without COVID-19 history: a multi-center real-world study.","authors":"Hanbo Pan, Hang Chen, Wanyu Li, Yu Tian, Zhen Ge, Weicheng Kong, Zenan Gu, Ningyuan Zou, Hongda Zhu, Jiaqi Zhang, Yixing Tao, Junwei Ning, Jia Huang, Hui Yin, Ming Zhang, Chengwei Zhou, Hui Wang, Guodong Xu, Qingquan Luo","doi":"10.1177/17534666241298794","DOIUrl":"10.1177/17534666241298794","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease (COVID)-19 can lead to chronic lung damage and respiratory issues, potentially increasing surgical difficulty and risk for patients with non-small-cell lung cancer (NSCLC). However, the impacts of a COVID-19 history on early outcomes in NSCLC patients remain controversial.</p><p><strong>Objectives: </strong>To evaluate the effect of COVID-19 history on early outcomes in NSCLC patients and identify high-risk groups undergoing radical resection based on the largest Chinese multi-center real-world data to date.</p><p><strong>Design: </strong>Multi-center retrospective cohort study.</p><p><strong>Methods: </strong>NSCLC patients with (POCVD group) or without (NCVD group) a history of COVID-19 who underwent radical surgery at six institutions from January 2022 to January 2024 were retrospectively reviewed from a prospectively maintained database. Propensity-score matching (PSM) was utilized to minimize patient selection bias.</p><p><strong>Results: </strong>Out of 7932 cases included, PSM resulted in 3021 cases per group. The two groups were comparable regarding the proportion of male patients (52.0% vs 51.6%) and those aged ⩾70 years (13.3% vs 13.8%). Although the two groups had comparable incidences of complications with Clavien-Dindo grades ⩾II (13.0% vs 14.4%, <i>p</i> = 0.117), the POCVD group had longer surgical durations (120.87 ± 40.23 min vs 110.74 ± 38.76 min, mean difference (95% confidence interval (CI) = 10.13 (8.138-12.122)) and higher rates of respiratory complications than the NCVD group. Subgroup logistic regression analysis indicated that patients aged ⩾70 years (odds ratio (OR) (95% CI) = 1.322 (1.022-1.876)) and those with a smoking history (OR (95% CI) = 1.235 (1.008-1.543)) had an increased risk of developing complications with Clavien-Dindo grades ⩾II. Further analysis confirmed that these high-risk patients experienced extended surgical durations, longer chest tube drainage, and prolonged postoperative hospital stay, along with increased postoperative respiratory complications following COVID-19.</p><p><strong>Conclusion: </strong>Generally, radical resection is safe for NSCLC patients with a COVID-19 history. However, these patients experienced prolonged surgical durations and a higher incidence of postoperative respiratory complications compared to those without a COVID-19 history. In addition, individuals aged ⩾70 years or with a smoking history faced elevated surgical risks following COVID-19.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241298794"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
iPREDICT: proof-of-concept study to develop a predictive model of changes in asthma control. iPREDICT:开发哮喘控制变化预测模型的概念验证研究。
IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666241266186
Mario Castro, Merrill Zavod, Annika Rutgersson, Magnus Jörntén-Karlsson, Bhaskar Dutta, Lynn Hagger

Background: The individualized PREdiction of DIsease Control using digital sensor Technology (iPREDICT) program was developed for asthma management using digital technology. Devices were integrated into daily lives of patients to establish a predictive model of asthma control by measuring changes from baseline health status with minimal device burden.

Objectives: To establish baseline disease characteristics of the study participants, detect changes from baseline associated with asthma events, and evaluate algorithms capable of identifying triggers and predicting asthma control changes from baseline data. Patient experience and compliance with the devices were also explored.

Design: This was a multicenter, observational, 24-week, proof-of-concept study conducted in the United States.

Methods: Patients (⩾12 years) with severe, uncontrolled asthma engaged with a spirometer, vital sign monitor, sleep monitor, connected inhaler devices, and two mobile applications with embedded patient-reported outcome (PRO) questionnaires. Prospective data were linked to data from electronic health records and transmitted to a secure platform to develop predictive algorithms. The primary endpoint was an asthma event: symptom worsening logged by patients (PRO); peak expiratory flow (PEF) < 65% or forced expiratory volume in 1 s < 80%; increased short-acting β2-agonist (SABA) use (>8 puffs/24 h or >4 puffs/day/48 h). For each endpoint, predictive models were constructed at population, subgroup, and individual levels.

Results: Overall, 108 patients were selected: 66 (61.1%) completed and 42 (38.9%) were excluded for failure to respond/missing data. Predictive accuracy depended on endpoint selection. Population-level models achieved low accuracy in predicting endpoints such as PEF < 65%. Subgroups related to specific allergies, asthma triggers, asthma types, and exacerbation treatments demonstrated high accuracy, with the most accurate, predictive endpoint being >4 SABA puffs/day/48 h. Individual models, constructed for patients with high endpoint overlap, exhibited significant predictive accuracy, especially for PEF < 65% and >4 SABA puffs/day/48 h.

Conclusion: This multidimensional dataset enabled population-, subgroup-, and individual-level analyses, providing proof-of-concept evidence for development of predictive models of fluctuating asthma control.

背景:利用数字传感器技术(iPREDICT)开发了个性化哮喘控制预测项目,旨在利用数字技术进行哮喘管理。将设备集成到患者的日常生活中,通过测量基线健康状况的变化来建立哮喘控制的预测模型,同时尽量减轻设备负担:目标:确定研究参与者的基线疾病特征,检测与哮喘事件相关的基线变化,评估能够识别触发因素并根据基线数据预测哮喘控制变化的算法。此外,还探讨了患者使用设备的体验和依从性:这是一项在美国进行的多中心、观察性、为期 24 周的概念验证研究:方法:患有严重、无法控制的哮喘的患者(⩾12 岁)使用肺活量计、生命体征监测仪、睡眠监测仪、连接吸入器的设备,以及两款内嵌患者报告结果 (PRO) 问卷的移动应用程序。前瞻性数据与电子健康记录数据相连,并传输到一个安全平台,用于开发预测算法。主要终点是哮喘事件:患者记录的症状恶化(PRO);呼气流量峰值(PEF)-2-激动剂(SABA)的使用(>8次/24小时或>4次/天/48小时)。针对每个终点,在人群、亚组和个体层面构建了预测模型:总共选取了 108 名患者:66 人(61.1%)完成了问卷调查,42 人(38.9%)因未做出回应/数据缺失而被排除。预测准确性取决于终点选择。针对终点重合度高的患者构建的个体模型显示出显著的预测准确性,尤其是对 PEF 4 SABA puffs/day/48 h 的预测:该多维数据集可进行人群、亚组和个体层面的分析,为开发哮喘控制波动预测模型提供了概念验证证据。
{"title":"iPREDICT: proof-of-concept study to develop a predictive model of changes in asthma control.","authors":"Mario Castro, Merrill Zavod, Annika Rutgersson, Magnus Jörntén-Karlsson, Bhaskar Dutta, Lynn Hagger","doi":"10.1177/17534666241266186","DOIUrl":"10.1177/17534666241266186","url":null,"abstract":"<p><strong>Background: </strong>The individualized PREdiction of DIsease Control using digital sensor Technology (iPREDICT) program was developed for asthma management using digital technology. Devices were integrated into daily lives of patients to establish a predictive model of asthma control by measuring changes from baseline health status with minimal device burden.</p><p><strong>Objectives: </strong>To establish baseline disease characteristics of the study participants, detect changes from baseline associated with asthma events, and evaluate algorithms capable of identifying triggers and predicting asthma control changes from baseline data. Patient experience and compliance with the devices were also explored.</p><p><strong>Design: </strong>This was a multicenter, observational, 24-week, proof-of-concept study conducted in the United States.</p><p><strong>Methods: </strong>Patients (⩾12 years) with severe, uncontrolled asthma engaged with a spirometer, vital sign monitor, sleep monitor, connected inhaler devices, and two mobile applications with embedded patient-reported outcome (PRO) questionnaires. Prospective data were linked to data from electronic health records and transmitted to a secure platform to develop predictive algorithms. The primary endpoint was an asthma event: symptom worsening logged by patients (PRO); peak expiratory flow (PEF) < 65% or forced expiratory volume in 1 s < 80%; increased short-acting β<sub>2</sub>-agonist (SABA) use (>8 puffs/24 h or >4 puffs/day/48 h). For each endpoint, predictive models were constructed at population, subgroup, and individual levels.</p><p><strong>Results: </strong>Overall, 108 patients were selected: 66 (61.1%) completed and 42 (38.9%) were excluded for failure to respond/missing data. Predictive accuracy depended on endpoint selection. Population-level models achieved low accuracy in predicting endpoints such as PEF < 65%. Subgroups related to specific allergies, asthma triggers, asthma types, and exacerbation treatments demonstrated high accuracy, with the most accurate, predictive endpoint being >4 SABA puffs/day/48 h. Individual models, constructed for patients with high endpoint overlap, exhibited significant predictive accuracy, especially for PEF < 65% and >4 SABA puffs/day/48 h.</p><p><strong>Conclusion: </strong>This multidimensional dataset enabled population-, subgroup-, and individual-level analyses, providing proof-of-concept evidence for development of predictive models of fluctuating asthma control.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241266186"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The difference between limited driving pressure ventilation and low tidal volume strategies in adults with acute lung failure. 成人急性肺衰竭患者有限驱动压力通气与低潮气量策略的区别。
IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666241271019
Takuya Hiramoto
{"title":"The difference between limited driving pressure ventilation and low tidal volume strategies in adults with acute lung failure.","authors":"Takuya Hiramoto","doi":"10.1177/17534666241271019","DOIUrl":"10.1177/17534666241271019","url":null,"abstract":"","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241271019"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11342313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Synapse 3D system (Version 4.4) and DirectPath system (Version 2.0) in virtual bronchoscopic navigation application for peripheral pulmonary nodules. Synapse 3D系统(Version 4.4)与DirectPath系统(Version 2.0)在周围性肺结节虚拟支气管镜导航中的应用比较
IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2024-01-01 DOI: 10.1177/17534666241307182
Xiang Li, Sen Tian, Yifei Zhang, Hui Chen, Yilin Chen, Qin Wang, Wei Zhang, Hui Shi, Haidong Huang, Xiaping Shen, Yao Fang, Lei Qu, Zhenhong Hu, Yuchao Dong, Chong Bai

Background: Differences between virtual bronchoscopic navigation (VBN) systems and their impacts on the diagnostic yield of transbronchial biopsy (TBB) of peripheral pulmonary nodules (PPNs) remain unclear.

Objectives: To compare the Synapse 3D system (Version 4.4, Fujifilm, Japan) and DirectPath system (Version 2.0, Olympus, Japan) in the VBN application of PPNs.

Design: Retrospective study with self-paired design and exploratory study with retrospective cohort design.

Methods: The study analyzed patients with PPNs using the Synapse 3D system (Group S) and DirectPath system (Group D) and compared differences between the two groups in bronchial tree reconstruction, navigation pathway planning, and VBN-assisted TBB of PPNs.

Results: In all, 289 patients were analyzed ultimately. Bronchial tree reconstruction quality was better in Group S (p < 0.001). Navigation pathway planning duration in Group S was longer than that in Group D (median 1.35 vs 1.04 s, p < 0.001). Automated navigation pathway planning success rate in Group S was higher than that in Group D (36.7% vs 19.7%, p < 0.001), and CT image reconstruction parameter and nodule diameter, bronchus sign, and distance from the hilum had significant effects on it in both groups. Fifty-six patients in Group S and forty-two patients in Group D were analyzed ultimately. The localization success rate and diagnostic yield of PPNs between the two groups were not significantly different (85.3% vs 91.2% and 67.6% vs 61.8%, respectively, p > 0.05).

Conclusion: Synapse 3D system (Version 4.4) and DirectPath system (Version 2.0) had their own merits. Localization success rate and diagnostic yield of VBN-assisted TBB were of no statistical difference for these two VBN systems. Improvements in segmentation algorithms of VBN systems and using the most suitable chest CT scan data for them may be the breakthrough to improve the efficiency of VBN, especially for poor experienced interventional physicians.

背景:虚拟支气管镜导航(VBN)系统之间的差异及其对经支气管活检(TBB)外周肺结节(ppn)诊出率的影响尚不清楚。目的:比较Synapse 3D系统(Version 4.4, Fujifilm, Japan)和DirectPath系统(Version 2.0, Olympus, Japan)在ppn的VBN应用中的差异。设计:自配对设计的回顾性研究和回顾性队列设计的探索性研究。方法:采用Synapse 3D系统(S组)和DirectPath系统(D组)对PPNs患者进行分析,比较两组在支气管树重建、导航通路规划和vbn辅助PPNs TBB方面的差异。结果:共分析289例患者。S组支气管树重建质量较好(p < 0.05)。结论:Synapse 3D系统(Version 4.4)和DirectPath系统(Version 2.0)各有优点。两种VBN辅助TBB的定位成功率和诊出率无统计学差异。改进VBN系统的分割算法,使用最适合VBN的胸部CT扫描数据,可能是提高VBN效率的突破口,特别是对于经验不足的介入医生而言。
{"title":"Comparison of Synapse 3D system (Version 4.4) and DirectPath system (Version 2.0) in virtual bronchoscopic navigation application for peripheral pulmonary nodules.","authors":"Xiang Li, Sen Tian, Yifei Zhang, Hui Chen, Yilin Chen, Qin Wang, Wei Zhang, Hui Shi, Haidong Huang, Xiaping Shen, Yao Fang, Lei Qu, Zhenhong Hu, Yuchao Dong, Chong Bai","doi":"10.1177/17534666241307182","DOIUrl":"10.1177/17534666241307182","url":null,"abstract":"<p><strong>Background: </strong>Differences between virtual bronchoscopic navigation (VBN) systems and their impacts on the diagnostic yield of transbronchial biopsy (TBB) of peripheral pulmonary nodules (PPNs) remain unclear.</p><p><strong>Objectives: </strong>To compare the Synapse 3D system (Version 4.4, Fujifilm, Japan) and DirectPath system (Version 2.0, Olympus, Japan) in the VBN application of PPNs.</p><p><strong>Design: </strong>Retrospective study with self-paired design and exploratory study with retrospective cohort design.</p><p><strong>Methods: </strong>The study analyzed patients with PPNs using the Synapse 3D system (Group S) and DirectPath system (Group D) and compared differences between the two groups in bronchial tree reconstruction, navigation pathway planning, and VBN-assisted TBB of PPNs.</p><p><strong>Results: </strong>In all, 289 patients were analyzed ultimately. Bronchial tree reconstruction quality was better in Group S (<i>p</i> < 0.001). Navigation pathway planning duration in Group S was longer than that in Group D (median 1.35 vs 1.04 s, <i>p</i> < 0.001). Automated navigation pathway planning success rate in Group S was higher than that in Group D (36.7% vs 19.7%, <i>p</i> < 0.001), and CT image reconstruction parameter and nodule diameter, bronchus sign, and distance from the hilum had significant effects on it in both groups. Fifty-six patients in Group S and forty-two patients in Group D were analyzed ultimately. The localization success rate and diagnostic yield of PPNs between the two groups were not significantly different (85.3% vs 91.2% and 67.6% vs 61.8%, respectively, <i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>Synapse 3D system (Version 4.4) and DirectPath system (Version 2.0) had their own merits. Localization success rate and diagnostic yield of VBN-assisted TBB were of no statistical difference for these two VBN systems. Improvements in segmentation algorithms of VBN systems and using the most suitable chest CT scan data for them may be the breakthrough to improve the efficiency of VBN, especially for poor experienced interventional physicians.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241307182"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11648045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nebulization versus metered-dose inhaler and spacer in bronchodilator responsiveness testing: a retrospective study 支气管扩张剂反应性测试中雾化与计量吸入器和喷雾器的对比:一项回顾性研究
IF 4.3 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2023-12-10 DOI: 10.1177/17534666231214134
Rongli Lu, Ying Li, Chengping Hu, Pinhua Pan, Qiaohong Zhao, Ruoxi He
Background: The recommended delivery mode for bronchodilators in bronchodilator responsiveness (BDR) testing remains controversial. Objective: To compare the efficacy of salbutamol administration using a nebulizer versus a metered-dose inhaler (MDI) with spacer in BDR testing. Design: A retrospective study. Methods: This study examined the data of patients with chronic obstructive pulmonary disease who completed BDR testing between 1 December 2021 and 30 June 2022, at Xiangya Hospital, Central South University. After administering 400 μg of salbutamol through an MDI with spacer or 2.5 mg using a nebulizer, the changes in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were analyzed in patients with moderate-to-very severe spirometric abnormalities [pre-bronchodilator FEV1 percentage predicted values (FEV1%pred) ⩽59%]. Significant responsiveness was assessed as >12% and >200 mL improvement in FEV1 and/or FVC or >10% increase in FEV1%pred or FVC percentage predicted values (FVC%pred) from pre- to post-bronchodilator administration. Results: Of the enrolled 894 patients, 83.2% were male (median age, 63 years). After propensity score matching, 240 pairs of patients were selected. The increment in FEV1 and increased FEV1 relative to the predicted value (ΔFEV1%pred) were significantly higher in patients <65 years and those with severe spirometric abnormalities in the nebulization group than patients in the MDI group (all p < 0.05). Compared with MDI with spacer, patients who used nebulization had a 30 mL greater increase in ΔFEV1 (95% CI: 0.01–0.05, p = 0.004) and a 1.09% greater increase in ΔFEV1%pred (95% CI: 0.303–1.896, p = 0.007) from baseline. According to the > 12% and >200 mL increase criterion, the significant BDR rate with nebulization was 1.67 times higher than that with an MDI with spacer (OR = 1.67, 95% CI: 1.13–2.47, p = 0.009). Conclusion: Salbutamol delivered using a nebulizer may be preferable to an MDI with spacer in certain circumstances. Nebulization has the potential to increase responsiveness to salbutamol in BDR testing.
背景:在支气管扩张剂反应性(BDR)测试中,支气管扩张剂的推荐给药方式仍然存在争议。目的:比较沙丁胺醇雾化给药与带间隔剂的计量吸入器(MDI)在BDR检测中的疗效。设计:回顾性研究。方法:本研究检查了2021年12月1日至2022年6月30日在中南大学湘雅医院完成BDR检测的慢性阻塞性肺疾病患者的数据。分析中度至极重度肺功能异常患者经间隔剂吸入沙丁胺醇400 μg或雾化吸入2.5 mg后的用力呼气量(FEV1)和用力肺活量(FVC)变化[支气管扩张剂前FEV1百分比预测值(FEV1%pred)≥59%]。显着反应性评估为FEV1和/或FVC改善>12%和> 200ml,或FEV1%pred或FVC百分比预测值(FVC%pred)从支气管扩张剂使用前到使用后增加>10%。结果:入组的894例患者中,83.2%为男性(中位年龄63岁)。经倾向评分匹配后,选取240对患者。FEV1的增量和FEV1的增加相对于预测值(ΔFEV1%pred)在12%和>200 mL的增加标准中均显著高于雾化治疗组,显著BDR率是有间隔的MDI组的1.67倍(OR = 1.67, 95% CI: 1.13 ~ 2.47, p = 0.009)。结论:在某些情况下,沙丁胺醇雾化器给药优于带间隔剂的MDI。在BDR试验中,雾化有可能增加对沙丁胺醇的反应性。
{"title":"Nebulization versus metered-dose inhaler and spacer in bronchodilator responsiveness testing: a retrospective study","authors":"Rongli Lu, Ying Li, Chengping Hu, Pinhua Pan, Qiaohong Zhao, Ruoxi He","doi":"10.1177/17534666231214134","DOIUrl":"https://doi.org/10.1177/17534666231214134","url":null,"abstract":"Background: The recommended delivery mode for bronchodilators in bronchodilator responsiveness (BDR) testing remains controversial. Objective: To compare the efficacy of salbutamol administration using a nebulizer versus a metered-dose inhaler (MDI) with spacer in BDR testing. Design: A retrospective study. Methods: This study examined the data of patients with chronic obstructive pulmonary disease who completed BDR testing between 1 December 2021 and 30 June 2022, at Xiangya Hospital, Central South University. After administering 400 μg of salbutamol through an MDI with spacer or 2.5 mg using a nebulizer, the changes in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were analyzed in patients with moderate-to-very severe spirometric abnormalities [pre-bronchodilator FEV1 percentage predicted values (FEV1%pred) ⩽59%]. Significant responsiveness was assessed as >12% and >200 mL improvement in FEV1 and/or FVC or >10% increase in FEV1%pred or FVC percentage predicted values (FVC%pred) from pre- to post-bronchodilator administration. Results: Of the enrolled 894 patients, 83.2% were male (median age, 63 years). After propensity score matching, 240 pairs of patients were selected. The increment in FEV1 and increased FEV1 relative to the predicted value (ΔFEV1%pred) were significantly higher in patients <65 years and those with severe spirometric abnormalities in the nebulization group than patients in the MDI group (all p < 0.05). Compared with MDI with spacer, patients who used nebulization had a 30 mL greater increase in ΔFEV1 (95% CI: 0.01–0.05, p = 0.004) and a 1.09% greater increase in ΔFEV1%pred (95% CI: 0.303–1.896, p = 0.007) from baseline. According to the > 12% and >200 mL increase criterion, the significant BDR rate with nebulization was 1.67 times higher than that with an MDI with spacer (OR = 1.67, 95% CI: 1.13–2.47, p = 0.009). Conclusion: Salbutamol delivered using a nebulizer may be preferable to an MDI with spacer in certain circumstances. Nebulization has the potential to increase responsiveness to salbutamol in BDR testing.","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"4 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic Advances in Respiratory Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1